Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
National Handwashing Awareness Week is from Dec. 6 to 12, and a Geisinger physician advises that with the presence of the H1N1 virus this year, handwashing is more important than ever.
Though there are signs the H1N1 (swine flu) has peaked in the U.S. and Canada, a WHO flu expert said Thursday it is too early to declare the pandemic over, Canadian Press reports.
PuriCore, the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, was named as winner of the Emerging Life Sciences Company of the Year award, at the Eastern Technology Council’s 17th annual Enterprise Awards gala.
Following reports from Canada's Public Health Agency that six patients had suffered allergic reactions after receiving the shot, GlaxoSmithKline plc has voluntarily placed a hold on a single batch of the AS03 adjuvanted H1N1 vaccine Arepanrix in Canada as a precautionary measure.
Adaptive vaccination strategies, based on age patterns of hospitalizations and deaths monitored in real-time during the early stages of a pandemic, outperform seasonal influenza vaccination allocation strategies, according to findings reported Dec. 3 by researchers, including two from Arizona State University, in the online journal PLoS ONE.
According to the World Health Organization, the human H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic level. Over 500,000 cases have been confirmed worldwide with at least 6,500 fatalities. Since there is no longer a requirement to test and report individual cases, these numbers undoubtedly understate the real situation.
The relatively low number of new cases created by a single case of H1N1 influenza indicates that mitigation strategies such as vaccination, social distancing and the use of antiviral drugs may help to lessen the final impact of the virus, suggests an epidemiological modelling study
A special issue of Deutsches -rzteblatt International contains the first scientific presentation of clinical experience with the novel influenza A virus (H1N1/09) in the German-speaking countries since the start of the pandemic.
Surgeons and other healthcare professionals specialising in solid organ transplants have been issued with expert advice to guide them through the complex clinical issues posed by the global H1N1 (swine flu) pandemic.
Following recent reports of clusters of Tamiflu resistance, the WHO on Wednesday recommended that patients with severely weakened immune systems who become infected with the H1N1 (swine flu) virus receive additional antiviral treatment as needed throughout the duration of their illness, Agence France-Presse reports. "
One of the lasting legacies of 2009 and looming challenges of 2010 is the H1N1 virus. Fears about contracting H1N1 (commonly known as the swine flu) have consumed many Americans for most of the year, so EarnMyDegree.com (http://www.earnmydegree.com), a web resource of EducationDynamics, which connects prospective students with online classes, commissioned a new study about whether flu-related worries have caused people to change their habits.
The Roche assay for the 2009 H1N1 influenza virus detects RNA from the 2009 H1N1 Influenza A virus and provides a rapid means of identification of patients infected with this virus. In order to ensure continued specificity and sensitivity of the Roche's Influenza A/H1N1 assay, Roche performs sequence comparisons with all available 2009 H1N1 Influenza Virus sequences on a regular basis.
Email security experts at Red Condor today issued a warning about the latest spam campaign claiming to be from the Center for Disease Control and Prevention (CDC) and requesting that recipients complete a "Personal H1N1 Vaccination Profile."
Roche announced today that it has begun shipping additional quantities of Tamiflu® (oseltamivir phosphate) oral suspension (liquid).
RSV is a respiratory virus that infects the lungs and breathing passages. While most healthy people recover from RSV infection, it can be severe in infants. According to the United States Centers for Disease Control and Prevention (CDC), RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the nation.
The number of H1N1 (swine flu) cases in the U.S. appears to be decreasing, the CDC said Tuesday, CQ HealthBeat reports. "Flu was widespread in 32 states by the end of the week of Nov. 21, a decrease from 43 states in the prior week and 46 states earlier this fall, according to the CDC," the news service writes. "
The Washington Post: "Citing the balky swine flu vaccination campaign and other shortcomings in the nation's medical defenses, a top Obama administration official has announced a major review of the government's efforts to develop new protections against pandemics, bioterrorism and other health threats."
Novavax, Inc. today reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine. Novavax is conducting this study in collaboration with Avimex Laboratories of Mexico to support registration of the vaccine in Mexico and potentially other countries.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has received its fourth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for the national purchase plan.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will participate in and present data at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in Washington, DC Dec. 2-4, 2009.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.